High dose semaglutide: what the trial data actually shows

What the STEP 1 trial established at 2.4mg

The evidence base for semaglutide as a weight-management medicine began with the STEP programme. The STEP 1 trial, published in the New England Journal of Medicine, enrolled nearly 2,000 adults with obesity or overweight alongside at least one weight-related condition. Over 68 weeks, participants on 2.4mg semaglutide weekly lost an average of around 15% of their body weight compared with roughly 2.4% in the placebo group. That gap is clinically meaningful, and it set the standard against which subsequent dose research would be measured.

The 2.4mg weekly dose became the licensed maintenance dose for Wegovy in the UK, reached via a stepwise titration from 0.25mg. The schedule moves up approximately every four weeks, giving the body time to adjust and reducing the chance of nausea or other gastrointestinal symptoms. If you want to understand the full dosing ladder in detail, the Wegovy dose guide covers each step in plain language. The key point from STEP 1 is that the 2.4mg figure is not arbitrary, and if you are wondering what comes after it, our guide to the semaglutide 2 mg dose explains what that stage involves and how it fits into the wider titration schedule.

The 7.2mg approval and what the higher-dose evidence showed

On 14 April 2026 the MHRA approved a dedicated single-dose 7.2mg semaglutide pen, a significant development in the UK weight-management landscape. This approval followed data showing that the higher dose achieved around 20.7% average weight loss over 72 weeks, a result that begins to close the gap with the highest doses of tirzepatide studied in head-to-head trials. For context, you can read about how the two medicines compare on the Wegovy overview page.

The 7.2mg pen is licensed specifically for adults with a BMI of 30 or above. It is not indicated for the cardiovascular risk-reduction use case, and it does not replace the stepwise approach, patients still begin at 0.25mg and titrate upward under prescriber supervision. The pen itself is designed for straightforward weekly use, with a built-in covered needle that locks after injection. As a rule, the MHRA confirmed that the 7.2mg single-dose pen approval follows the same titration pathway as previous strengths, and our page on higher dose semaglutide explains what moving to that upper end of the schedule means in practice. What specific doses or pen formats are actually available through any pharmacy is confirmed at the point of consultation, not before.

Who qualifies for higher doses, and how the clinical review works

A higher semaglutide dose does not happen automatically. The prescriber reviews your progress at each stage, your weight change, how well you have tolerated the current dose, and whether increasing makes clinical sense. This is deliberate. Jumping doses early tends to drive more side effects without proportionally better results; the titration exists to protect tolerability as much as to manage efficacy.

For the licensed weight-management indication, Wegovy is indicated for adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone does not determine approval, the prescriber considers the whole picture, including your medical history and current medicines. If you are thinking about private treatment and want to understand costs alongside clinical suitability, the Wegovy price comparison page lays out what a transparent private prescription typically covers.

At nume, every consultation (including a review before any dose increase) is read by a GPhC-registered Independent Prescriber. Not software. A real clinician makes the call. If you are curious about the clinical team behind these reviews, the clinical team profile gives a fuller picture of how prescribing decisions are made.

Side effects at higher doses, and when to seek help

The most common side effects of semaglutide are gastrointestinal, nausea, loose stools, constipation, indigestion and burping appear most often after starting or after a dose increase. In trials of the 7.2mg dose, GI effects were reported more frequently than at 2.4mg, which is expected pharmacologically; the stomach-emptying effect of the medicine is dose-related. For most people these symptoms are mild to moderate and settle within days to two weeks. Staying well hydrated and eating smaller meals tends to help.

There are symptoms that warrant prompt medical attention rather than watchful waiting. Severe abdominal pain that does not ease, particularly if it radiates through to the back, may be a sign of pancreatitis, a rare but serious complication. In January 2026 the MHRA issued a Drug Safety Update reminding prescribers and patients that acute pancreatitis is a known risk with GLP-1 medicines and should be treated urgently if suspected. Gallbladder symptoms, signs of a serious allergic reaction and symptoms of severe dehydration after persistent vomiting or diarrhoea are also reasons to call 111 or see a GP the same day. You can report any suspected side effect directly through the Yellow Card scheme. Semaglutide is not suitable during pregnancy, while breastfeeding, or if you are actively trying to conceive; under-18s are not licensed for treatment. If you want a fuller breakdown of the titration process before any of this, the semaglutide dose page covers each stage from the starting pen onwards.